Articles from Inocras

M42, a global health leader powered by artificial intelligence (AI), technology and genomics, and San Diego-based bioinformatics-led company Inocras, have announced a strategic collaboration to advance blood-based monitoring for cancer recurrence in the UAE. Through this partnership, the organizations will deploy Inocras’ MRDVision™ platform—a whole-genome technology suite combining comprehensive genomic profiling with personalized blood assays to detect molecular residual disease (MRD) via circulating tumor DNA (ctDNA), identifying traces of cancer that may remain after treatment and can lead to recurrence.

Inocras, a bioinformatics-led company harnessing the power of whole genome data and proprietary analytics to deliver curated insights that advance precision health, today announced that “DNAChunker: Learnable Tokenization for DNA Language Models,” a joint research paper with the Korea Advanced Institute of Science and Technology (KAIST), has been accepted for paper publication at the International Conference on Machine Learning (ICML) 2026.

Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, today announced that new real-world evidence evaluating whole-genome sequencing-based homologous recombination deficiency phenotyping has been accepted for online publication at the 2026 American Society of Clinical Oncology Annual Meeting.

Researchers from Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to advance precision health, and the Broad Institute of MIT and Harvard will jointly present new insights from a collaborative initiative to analyze large-scale whole genome data during the AACR Annual Meeting 2026 in San Diego. The collaboration delivers one of the largest cancer whole-genome analyses from over 8,000 cancer whole-genomes, generated by the NCI’s The Cancer Genome Atlas (TCGA), across more than 30 cancer types.

Researchers at Inocras, a bioinformatics-led precision health company harnessing the power of whole-genome sequencing (WGS) data and proprietary analytics, and the Broad Institute jointly announced the upcoming release of key insights from whole-genome analysis of over 8,000 public cancer whole genomes. This analysis aims to deliver one of the largest genome-wide landscapes of somatic mutations across human pan-cancers.

Inocras, a bioinformatics-led company harnessing the power of whole genome data and proprietary analytics to deliver curated insights that advance precision health, today announced a groundbreaking cancer foundation model trained on 2,882 whole genomes across diverse cancer types, marking a major advance in applying AI to precision oncology. Developed in collaboration with the Korea Advanced Institute of Science and Technology (KAIST), the model couples a novel learnable tokenization method with a cancer-aware embedding framework that integrates diverse genomic features into patient-level representations, capturing the molecular patterns that drive tumor biology and clinical outcomes.

Today, Fore Genomics, a leader in pediatric genetic health screening, announced a strategic partnership with Inocras, a leading innovator in whole genome sequencing (WGS) and AI-powered genetic analysis technologies, to enhance Fore’s proprietary pediatric and newborn health screening services.